Insider Selling: Biodesix, Inc. (NASDAQ:BDSX) Insider Sells 16,748 Shares of Stock

Biodesix, Inc. (NASDAQ:BDSX) insider Gary Anthony Pestano sold 16,748 shares of the stock in a transaction dated Tuesday, February 11th. The stock was sold at an average price of $0.92, for a total transaction of $15,408.16. Following the transaction, the insider now directly owns 156,008 shares of the company’s stock, valued at approximately $143,527.36. This trade represents a 9.69 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Biodesix Stock Down 1.1 %

Shares of BDSX traded down $0.01 during mid-day trading on Wednesday, hitting $0.94. 170,859 shares of the company’s stock were exchanged, compared to its average volume of 460,809. The company has a market cap of $136.74 million, a price-to-earnings ratio of -2.41 and a beta of 1.06. Biodesix, Inc. has a fifty-two week low of $0.86 and a fifty-two week high of $2.04. The company has a debt-to-equity ratio of 1.30, a quick ratio of 3.40 and a current ratio of 3.40. The stock’s 50-day moving average is $1.26 and its 200-day moving average is $1.49.

Institutional Trading of Biodesix

Several hedge funds have recently added to or reduced their stakes in BDSX. Barclays PLC increased its stake in Biodesix by 1,140.5% in the third quarter. Barclays PLC now owns 23,036 shares of the company’s stock valued at $41,000 after purchasing an additional 21,179 shares during the last quarter. HighTower Advisors LLC grew its position in Biodesix by 17.1% in the 4th quarter. HighTower Advisors LLC now owns 153,934 shares of the company’s stock valued at $236,000 after buying an additional 22,500 shares during the last quarter. Landscape Capital Management L.L.C. purchased a new position in Biodesix in the 3rd quarter valued at $262,000. Stephens Inc. AR acquired a new stake in Biodesix in the fourth quarter valued at $303,000. Finally, Geode Capital Management LLC lifted its holdings in Biodesix by 2.8% in the fourth quarter. Geode Capital Management LLC now owns 827,199 shares of the company’s stock valued at $1,266,000 after acquiring an additional 22,623 shares during the period. Institutional investors and hedge funds own 20.96% of the company’s stock.

Biodesix Company Profile

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.